Table 4.
Prognostic factors of the outcome’s pregnancy related to the endometrial treatments.
| Characteristics a | Failure***(n=53) | Live Birth** (n= 51) | OR | OR adjusted # |
|---|---|---|---|---|
|
Treatment for endometrial thickness <7 mm and/or endometrial volume < 2ml |
19 (51%) | 18 (69%) | 0.98 [0.44-2.17] | 1.10 [0.47-2.61] |
| Diagnosis of Uterine Immune Profile | ||||
| Normal | 18 (69%) | 8 (31%) | ||
| Dysregulated | 35 (45%) | 43 (55%) | 2.77 [1.10-7.44] | 3.39 [1.27-9.84] |
| Scratching/endometrial biopsy/hcg | 12 (50%) | 12 (50%) | 2.25 [0.72-7.38] | 2.55 [0.75-9.24] |
| Immunotherapy | 14 (36%) | 25 (64%) | 4.02 [1.43-12.1] | 4.99 [1.65-16.5] |
| Endometrial biopsy/hcg/immunotherapy | 9 (60%) | 6 (40%) | 1.5 [0.39-5.72] | 2.07 [0.48-9.19] |
| Treatment by immunotherapy (hight immune activation and mixted profile) | ||||
| Without therapy control | 20 (47%) | 22 (53%) | 2.73 [0,70-13,6] | 2.38 [0.51-14.1] |
| With therapy control | 3 (25%) | 9 (75%) | 1 | 1 |
a
Continuous data are presented as mean ± standard deviation; categorical data are presented as number (percentage).
**The live birth was defined as delivery of a viable infant at 22 weeks or more of gestation.
***The failure Group included early pregnancy loss and patients who have not had a pregnancy.
#adjusted for age and AMH.
Results from the univariate and multivariate analysis.